Development and validation of the Immune Profile Score (IPS), a novel multiomic algorithmic assay for stratifying outcomes in a real-world cohort of patients with advanced solid cancer treated with immune checkpoint inhibitors.

Journal: Journal for immunotherapy of cancer
Published Date: May 30, 2025

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions.

Authors

  • Alia D Zander
    Tempus AI Inc, Chicago, Illinois, USA.
  • Rossin Erbe
    Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Convergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Yan Liu
    Department of Clinical Microbiology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, People's Republic of China.
  • Ailin Jin
    Tempus AI Inc, Chicago, Illinois, USA.
  • Seung Won Hyun
    Tempus AI Inc, Chicago, Illinois, USA.
  • Sayantoni Mukhopadhyay
    Tempus AI Inc, Chicago, Illinois, USA.
  • Ben Terdich
    Tempus AI Inc, Chicago, Illinois, USA.
  • Mario G Rosasco
    Tempus AI Inc, Chicago, Illinois, USA.
  • Nirali Patel
    Tempus AI Inc, Chicago, Illinois, USA.
  • Brett M Mahon
    Tempus Labs, Chicago, IL, USA.
  • A Kate Sasser
    Tempus AI Inc, Chicago, Illinois, USA.
  • Michelle A Ting-Lin
    Tempus AI Inc, Chicago, Illinois, USA.
  • Halla Nimeiri
    Tempus AI Inc, Chicago, Illinois, USA.
  • Justin Guinney
    Computational Oncology, Sage Bionetworks, Seattle, Washington.
  • Douglas Adkins
    Washington Univ, St. Louis, Missouri, USA.
  • Matthew Zibelman
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Kyle A Beauchamp
    Tempus AI Inc, Chicago, Illinois, USA.
  • Chithra Sangli
    Tempus AI Inc, Chicago, Illinois, USA.
  • Michelle M Stein
    Tempus AI Inc, Chicago, Illinois, USA.
  • Timothy Taxter
    Tempus AI Inc, Chicago, Illinois, USA.
  • Timothy Chan
    Center for Immunotherapy and Precision Immuno-oncology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Sandip P Patel
    University of California at San Diego Moores Cancer Center, La Jolla, CA.
  • Ezra E W Cohen
    Tempus AI Inc, Chicago, Illinois, USA ezra.cohen@tempus.com.

Keywords

External Resources

Popular Topics
Recent Journals